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Background: The aim of this study was to evaluate the expression of the cell adhesion-related glycoproteins
MUC-1, β-catenin and E-cadherin in multicentric/multifocal breast cancer in comparison to unifocal disease in order
to identify potential differences in the biology of these tumor types.
Methods: A retrospective analysis was performed on the expression of MUC1, β-catenin and E-cadherin by
immunohistochemistry on tumor tissues of a series of 112 breast cancer patients (total collective) treated in Munich
between 2000 and 2002. By matched-pair analysis, 46 patients were entered into two comparable groups of 23
patients after categorizing them as having multicentric/multifocal or unifocal breast cancer. Matching criteria were
tumor size, histology grade and lymph node status; based on these criteria, patients were distributed equally
between the two groups (p = 1.000 each). Data were analyzed with the Kruskal-Wallis and the Mann–Whitney tests.
Results: In the matched groups, we found a significantly down-regulated expression of E-cadherin in
multicentric/multifocal breast cancer compared to unifocal disease (p = 0.024). The total collective showed even
higher significance with a value of p < 0.0001. In contrast, no significant differences were observed in the
expression of β-catenin between multicentric/multifocal and unifocal tumors (p = 0.636 and p = 0.914, respectively).
When comparing the expression of MUC1, E-cadherin and β-catenin within the unifocal group, we found a significant
positive correlation between E-cadherin and β-catenin (p = 0.003). In the multicentric/multifocal group we observed, in
contrast to the unifocal group, a significant decrease of MUC1 expression with increased grading (p = 0.027).
Conclusion: This study demonstrates that multicentric/multifocal and unifocal breast cancers with identical
TNM-staging clearly differ in the expression level of E-cadherin. We suggest that the down-regulation of E-cadherin in
multicentric/multifocal breast cancer is causally connected with the worse prognosis of this tumor type.
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Tumor-node-metastasis (TNM) staging has been the stand-
ard method for breast cancer classification for more than
fifty years. During this time, however, the classification pro-
cedure has changed substantially. In 2003, the 6th edition
of the TNM classification was established [1-3]. The T cat-
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distribution, and reproduction in any mediumthese changes [3]. The prognosis of breast cancer patients
depends on two different types of factors: tumor size as a
time-dependent marker of tumor biology, and biological
factors (i.e., histological grade) which represent tumor
aggressiveness [4]. Other prognostic factors include the
estrogen and progesterone receptor status as well as the
relative number of mitotic figures (MF/10HPF) [5,6].
Treatment plans are following worldwide prevailing sug-
gestions, including those of the TNM system. However, the
TNM classification has changed, and treatment recommen-
dations and the treatments themselves have been modified.
Breast-conserving treatment, once a controversial issue, isCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tomy for surgically manageable breast cancer.
In a recent study we have demonstrated that focality
is an independent prognostic factor by comparing
multicentric/multifocal and unifocal breast cancer [7].
Therefore, additional biological factors seem to play an
important but not well understood role in multicentric/
multifocal breast cancers.
The above-mentioned established prognostic factors
[4,8,9] as well as potential new factors, such as the
E-cadherin-related transcriptional repressor Snail or
the c-Jun activation domain-binding protein-1 (Jab1),
are multifunctional signaling proteins. The E-cadherin/
catenin complex is known to be a potent inhibitor of
cancer progression [10-13].
The disconnection of cell-cell adhesions is a fundamen-
tal step in the progression of cancer and metastasis that is
mediated by a variety of membrane proteins. The trans-
membrane protein E-cadherin, which is responsible for
calcium-dependent cell adhesions, is a widely studied
tumor suppressor. It is expressed predominantly in epithe-
lial cells, and its extracellular region has a Ca2+-dependent
homophilic adhesion function. Loss of E-cadherin has
been reported to induce epithelial-mesenchymal transition
in several cancers [14-16].
Epithelial mucin-1 (MUC1) is a complex transmembrane
glycoprotein. The larger, heavily glycosylated domain of the
MUC molecule is extracellularly expressed [17]. MUC1
exerts a number of different functions [18-23]. MUC1
undergoes characteristic modifications of its glycosylation
and cellular localization during malignant transformation
[24]. Many monoclonal antibodies have been developed to
MUC1 [17]. A novel antibody, PankoMab, was devel-
oped against a tumor-associated epitope of MUC1
[19]. In a previous paper, PankoMab was examined in
patients with breast cancer in comparison with two
other known antibodies. PankoMab was unique to the
effect that its staining was correlated with the estrogen
receptor expression [20].
The glycoprotein β-catenin interacts with both E-
cadherin and MUC1. The interaction between MUC1
and E-cadherin is mediated by β-catenin-binding and
interrupts E-cadherin-mediated cell-cell adhesions.
Signal transduction through β-catenin (the so-called
Wnt/β-catenin signaling pathway) has already been
thoroughly investigated [21]. This signal transduction
regulates the expression of a number of genes essential for
cell differentiation and proliferation. Alterations in this
pathway are implicated in diseases such as cancer [22].
The aim of this study was to compare the expression
of MUC1, E-cadherin and β-catenin in multicentric/
multifocal tumors with their expression in unifocal tumors
of identical tumor size according to TNM staging in order
to detect potential differences.Methods
Patients
Two groups were framed and investigated. Based on a
consecutive patient cohort consisting of 112 patients
documented and surgically treated for primary breast
cancer between 2000 and 2002 at the Department of
Gynecology of the University Hospital in Munich-
Innenstadt, 57 unifocal breast cancer patients and 55
patients with multicentric/multifocal disease formed
our total collective (TC). From the same patient co-
hort, two equivalent groups of 23 breast cancer pa-
tients with multicentric/multifocal vs. unifocal tumors
were selected using a matched paired analysis (MG)
(see Statistical Analysis section below). The Institutional
Review Board of the Ludwig Maximilians University
Munich, Germany, approved the study and all the patients
gave informed consent.
Unifocality versus multicentricity/multifocality were
determined by clinical examination, ultrasound and X-ray.
In addition, in a few cases nuclear magnetic resonance
imaging (NMRI), galactography or pneumocystography
was performed if necessary. These techniques were used
in a few cases, in which additional information regarding
focality was necessary. Moreover, those cases which failed
to confirm multicentricity/multifocality with respect to
the final histological examination were excluded.
Data were contemporaneously gathered for the unifocal
and multicentric/multifocal tumors. To be eligible, patients
were required to be free of disease, and they must have
been treated at the study site at the time of primary
diagnosis of resectable breast cancer. The tumor stage
at primary diagnosis was classified according to the
UICC TNM classification [23]. Tumor grading by WHO
(Nottingham grading respectively to Elston & Ellis modifi-
cation of Bloom-Richardson grading [25] was used, and
match criteria were tumor size, histology grade and lymph
node status, all of which were equally distributed between
the two groups (p = 1.0). The total collective was not
matched. We used this group to validate the results of the
matched group.
Surgical treatment
The primary surgical treatment consisted of either breast
conservation or modified radical mastectomy. Routine
axillary dissections were performed on levels I and II
lymph nodes, while level III lymph nodes were only ex-
cised in cases expressing macroscopic metastatic lesions
of the lower levels. For the diagnosis of lymph node me-
tastasis, single embedded lymph nodes were screened at
up to three levels.
The guidelines for chemotherapy and cytostatic regimes
changed substantially also within the observation time
of the study. Therefore the authors did not include
oncological treatment details.
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Immunohistochemistry was performed using a com-
bination of pressure cooker heating for antigen re-
trieval and the standard streptavidin-biotin-peroxidase
complex with the use of the mouse IgG-Vectastain Elite
ABC kit (Vector Laboratories, Burlingame, CA, USA).
Table 1 lists the mouse monoclonal antibodies used for
these experiments.
Formalin-fixed paraffin embedded tissue sections were
dewaxed using xylol for 15 min, rehydrated in an descend-
ing series of alcohols (100%, 96%, and 70%), and subjected
to epitope retrieval for 5 min in a pressure cooker using
sodium citrate buffer (pH 6.0). After cooling, sections
were washed twice in PBS. Endogenous peroxidase activity
was quenched by immersion in 3% hydrogen peroxide in
methanol for 20 min. Non-specific binding of the primary
antibodies was blocked by pretreatment of the sections
with diluted normal serum (10 ml PBS containing 150 μl
horse serum; Vector Laboratories, Servion, Switzerland)
for 20 min. Sections were then incubated with the primary
antibodies at room temperature for 60 min. After washing
with PBS, sections were incubated in diluted biotinylated
secondary antiserum (10 ml PBS containing 50 μl
horse serum; Vector Laboratories) for 30 min at room
temperature. After incubation with the avidin-biotin
peroxidase complex (diluted in 10 ml PBS, Vector
Laboratories) for 30 min and repeated washing steps
with PBS, visualization was performed with DAB substrate
(Dako, Glostrup, Denmark) for 2 min. Sections were
counterstained with Mayer‘s hematoxylin and dehydrated
in an ascending series of alcohols (50–98%), followed by
xylol. Finally, sections were embedded, but mounted and
covered. Negative controls were performed by replacing
the primary antibody with normal horse serum. Immuno-
histochemical staining was performed using an appropri-
ate positive control.
The intensity and distribution patterns of specific
immunohistochemical staining were evaluated using
the semi-quantitative immuno-reactive score (IRS). This
score was calculated by multiplying the staining intensity
(graded as 0 = no, 1 = weak, 2 = moderate and 3 = strong
staining) with the percentage of positively stained cells
(0 = no staining, 1 = <10% of cells, 2 = 11-50% of cells,Table 1 Antibodies employed












Berlin, Germany3 = 51-80% of cells and 4= >81% of cells stained). The
slides were examined by two independent observers.
Sections were examined using a Leitz microscope
(Wetzlar, Germany) with a 3CCD color camera (JVC,
Victor Company of Japan, Japan).
Statistical analysis
Data were entered into the database in a coded fashion.
Our total collective of 112 patients included 57 unifocal
breast cancer patients and 55 cases of multicentric/
multifocal tumors. Because of the uneven distribution
of prognostic factors in our original patient group of
46 cases that met the match criteria, a matched pair
analysis was performed. A total of 23 pairs of patients,
each consisting of one patient with unifocal and one
with multicentric/multifocal tumor lesions, were selected
according to the highest degree of equivalence in the
following hierarchical and sequential order: tumor size at
the time of primary diagnosis, histology grading, and lymph
node status. Each parameter was required to have a
p value > 0.50 to achieve intergroup homogeneity. We
deliberately matched patients based on the criteria at the
time of primary diagnosis. The computer software ‘Statistical
Package for the Social Sciences 15.0’ (SPSS Inc., Chicago, IL,
USA) was used to perform statistical analyses. We used
Kruskal-Wallis one-way analysis of variance to analyze our
data, which is a non-parametric method for testing equality
of population medians among groups. It is an extension of
the Mann–Whitney U test to 3 or more groups.
For survival analysis median immunoreactivity levels, as
determined by the IR-score, of each marker were employed
to split the collective into low vs. high expressing cases.
The following thresholds were used: E-Cadherin ≥ IRS 8,
beta-Catenin (membrane staining) ≥ IRS 8, beta-Catenin
(cytoplasma staining) ≥ IRS 4, MUC1 (membrane staining) ≥
IRS 8, MUC1 (cytoplasma staining) ≥ IRS 1. Kaplan-Meier
survival curves were drawn to compare survival times of
uni- vs. multifocal/-centric tumors and of high vs low
expressing cases, respectively. Differences in overall and
relapse-free survival were tested for significance by applying
the chi-square statistic of the log rank test.
P values below 0.05 were considered significant.
Results
All matching criteria (tumor size, histology grade and
lymph node status) were equally distributed between the
two groups (p = 1.0).
No significant difference was observed between the
two groups in terms of age (p = 0.104 in the matched
group and p = 0.533 in the total collective) or menopausal
status (MG: p = 0.291 and TC: p = 0.503). Regarding histo-
logical types of tumors, the total collective (TC) demon-
strated a statistically significant difference with p = 0.003
(see below), whereas no significant difference was found in
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patient characteristics of both groups.
Looking at the total collective, 55 patients were included







Number of patients 55 57




Absent (N0) 27 (50.0) 35 (62.5)
1-3 axillary LNM (pN1bi) 4 (7.4) 7 (12.5)
1-3 axillary LNM (pN1biii) 18 (33.3) 8 (14.3)
1-3 axillary LNM (pN1biv) 0 3 (5.4)
4-9 axillary LNM (pN2) 1 (1.9) 1 (1.8)
Unknown (pNx) 5 (9.1) 3 (5.3)
Histological Type .003
Ductal 35 (66) 39 (69.6)
Lobular 11 (20.8) 3 (5.4)
Ductal-lobular 4 (7.5) 3 (5.4)
Mucinous 1 (1.9) 2 (3.6)
Medullary 1 (1.9) 4 (7.1)
Micropapillary 1 (1.9) 2 (3.6)
Tubulary 0 3 (5.4)
Not specified 2 (3.6) 1 (1.8)
Menopausal Status .503
Premenopausal 13 (47.9) 16 (37.5)







Number of patients 23 23
Age 57 68 .104
Histological Type .120
Ductal 16 (69.6) 15 (65.2)
Lobular 5 (21.7) 3 (13.0)
Ductal-lobular 2 (8.7) 1 (4.3)
Medullary 0 1 (4.3)
Micropapillary 0 2 (8.7)
Not specified 0 1 (4.3)
Menopausal Status .291
Premenopausal 4 (18.8) 6 (26.1)
Perimenopausal 0 1 (4.3)
Postmenopausal 18 (81.8) 14 (60.9)
Unknown 1 (4.3) 2 (8.7)group. This group was not matched, so statistical ana-
lysis was performed according the matching criteria of
tumor size, lymph node status and histopathological
grading. Tumor size (p = 0.113), lymph node involvement
(p = 0.150), and histopathological grading (p = 0.068)
did not show any significant correlation with multicentric/
multifocal tumors versus unifocal tumors.
According to the histological tumor type, a significant
difference was observed in the incidence of invasive lobular
cancer in the multicentric/multifocal group in comparison
to the unifocal group. Of 14 patients suffering from invasive
lobular cancer, 11 had multicentric/multifocal disease,
whereas only 3 had unifocal breast cancer. The results were
different for invasive ductal tumors; out of 74 patients with
invasive ductal cancer, 35 had multicentric/multifocal
disease, and 39 had unifocal breast cancer. Looking at
the matched group, five patients had lobular multicentric/
multifocal breast cancer (21.7%), and three patients (13.6%)
had a lobular unifocal disease. Also, ductal carcinomas
did not differ significantly. Sixteen patients (69.6%) in
the multicentric/multifocal matched group had ductal
breast cancer, compared with 15 patients (68.2%) in the
unifocal group.
Regarding the expression of E-cadherin, lobular cancers
were not included in the statistical analysis of the two
groups. The total collective examined therefore included 54
unifocal and 44 multicentric/multifocal cancer tissues.
Compared to the multicentric/multifocal group, E-cadherin
expression was significantly higher in the unifocal group,
with a p-value of <0.0001. MG in this case included
32 patients (16 pairs). E-cadherin expression was also
significantly higher in the unifocal matched group
with p = 0.024 (Figure 1).
Looking at the grading within the total collectivegroup as
well as unifocal tumors, G2 (moderately differentiated)
tumors exhibited higher E-cadherin expression com-
pared to multifocal tumors (p = 0.001), as did G3
(poorly differentiated) tumors (p = 0.037). The matched
pair group underlined these results for G2 tumors and
revealed higher E-cadherin expression in unifocal tumors
compared with multicentric/multifocal tumors. The
p-value was 0.055 for G2 tumors, whereas G3 tumors
failed to demonstrate significance with p = 0.261 (Figure 1).
No significant differences in β-catenin expression
patterns were observed between multicentric/multi-
focal and unifocal tumors (p = 0.914) when comparing the
total collective, and the difference was also not significant
for the matched pairs (p = 0.636). Furthermore, β-catenin
expression showed no significant correlation with histology
grade within the total collective either for multicentric/
multifocal breast cancers (p = 0.564) or for unifocal disease
(data not shown, p = 0.635).
However, the cytoplasm ß-catenin was associated sig-
nificantly with a reduced overall survival (OS) in unifocal
Figure 1 E-cadherin expression in the total collective (A, B) and in the matched group (C, D) of unifocal (A, C) and multicentric/multifocal
(B, D) breast cancer; magnification 25× lens. Semiquantitative evaluation of staining results (IR score) is presented in box plots (E-G) for the total
collective and in the box plots (H-J) for the matched group with respect to differences between G2 and G3-tumors. The boxes represent the range
between the 25th and 75th percentiles with a horizontal line at the median. The bars delineate the 5th and 95th percentiles. The circles indicate
values more than 1.5 box lengths away from the median.
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found concerning survival in mulicentric/multifocal
tumors (Figure 2A).
The MUC1 expression also failed to demonstrate a
significant difference between unifocal and multicentric/
multifocal disease in both the MG (p = 0.840) and the TC
group (p = 0.183).
Analyzing differences with respect to histology grade,
no differences in MUC1 expression were observed
in the total collective among G1, G2 and G3 unifocaltumors (p = 0.840). In contrast, MUC1 expression in
multicentric/multifocal tumors was significantly dependent
on histology grade (decreasing from G1 to G3 at p = 0.027)
(Figure 3).
The PankoMab epitope demonstrated no difference
according to the histology grade when looking at the
cytoplasm staining. When looking at the overall sur-
vival (OS), the PankoMab epitope on the membrane
was associated with a better outcome, however only
significant in G2 and G3-unifocal tumors (Figure 2B).
Figure 2 ß-Catenin and MUC1 expression related to overall survival and focality. A: Cytoplasmic ß-catenin expression related to the overall
survival (OS) in unifocal and multicentric/multifocal tumors. B: PankoMab epitope on the membrane related to the overall survival (OS) in unifocal
and multicentric/multifocal tumors.
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tumors exhibited partial loss of MUC1 expression.
Discussion
We investigated in a previous study the prognostic dif-
ferences between multicentric/multifocal and unifocal
breast cancer [7]. In that study, patients were entered by
matched-pair analysis into two comparable groups of 288
patients after categorizing them as having multicentrical/
multifocal or unifocal breast cancers. Matching criteria
were tumor size, histology grade and hormone receptor
status, which were equally distributed between both groups
(p = 1.000 each). We demonstrated that multicentric/multi-
focal breast cancer is associated with a worse prognosis
compared to unifocal disease with an identical tumor sizeFigure 3 MUC1 (mPankoMab) membrane expression in the total collecti
tumor (B), and a G3 tumor (C); magnification 25× lens. The box plots (D, E
boxes represent the range between the 25th and 75th percentiles with a horiz[7]. However, Vlastots et al. investigated breast cancer
patients with early-stage disease and did not find an
increased risk of poor outcome with respect to
multicentricity. According to the authors, this study
supports the current tumor, node, metastasis staging
system [26].
On the contrary, Tot et al. also demonstrated recently,
that multifocality represents a negative prognostic param-
eter associated in this study with significantly increased
lymphnode metastasis (LNM) [27]. These findings were
confirmed by Tot et al. in further studies, that demon-
strated multifocality being associated with an increased risk
of LNM [28,29].
According to our study-collective of 112 patients, 55
patients were included in the multicentric/multifocalve of multicentric/multifocal breast cancer in a G1 tumor (A), a G2
) present a semiquantitative evaluation of staining results (IR score). The
ontal line at the median. The bars delineate the 5th and 95th percentiles.
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was not matched, and statistical analysis was performed
according the matching criteria of tumor size, lymph
node status and histopathological grading. Our results
did however not demonstrate any significant correlation
of lymph node metastasis when comparing multicentric/
multifocal and unifocal tumors. This result however has
to be interpreted in a critical manner to the effect that
the total collective however includes patients who were
matched according to the lymph nodes status.
However, it remained unclear whether the tendency of
breast cancer tumors to metastasize was a reflection of
the total tumor load or whether biological differences
play a decisive role. The 10-year survival rate was in-
vestigated by Boyages et al. who found – especially in
tumors > 2 cm – that the aggregate size of every focus
should be considered along with other prognostic factors
when comparing multifocal and unifocal breast cancer [30].
Aim of this manuscript was, to evaluate differences
in tumor biology, that might help explaining the above
mentioned differences. Tot et al. investigated multi-
focal and unifocal breast cancer according to the
immunophenotype (estrogen and progesterone recep-
tor expression, HER2 overexpression and expression of
basal-like markers, CK5/6, CK14, and epidermal growth
factor receptor). The auhors found higher rates of LNM in
the multifocal group, interestingly no differences with
respect to molecular phenotype [29]. These findings
were underlined by Pekar et al. who also demonstrated
that diffuse or multifocal distribution of the invasive
component is associated with cancer-related death in-
dependent of the molecular phenotype [31].
Bassarova et al. [32] investigated the cadherin/catenin
immunophenotype of multicentric tumor foci and bilateral
breast cancer. They found a greater similarity of the
primary tumor to its corresponding metastatic tumor than
to the contralateral primary tumor regarding the cadherin/
catenin immunophenotype [32]. Although different histo-
logical subtypes were examined (pleomorphic lobular, inva-
sive ductal of usual type, atypical medullary carcinomas,
mucinous and invasive micro papillary carcinomas), dif-
ferences in the tumor biology were obvious and could
be anticipated. The present study was intended to analyze
some of the potential factors involved.
β-catenin is involved in cell-cell adhesions and is a
transcriptional regulator in the Wnt signaling pathway
[33], furthermore it is consequently involved in the
development of human malignancies. Lopez-Knowles
et al. [34] investigated immunohistochemically the ex-
pression of β-catenin in 292 patients with invasive
ductal breast cancers. The authors demonstrated an
association between a high cytoplasmic expression of
β-catenin and a high tumor grade (p = 0.004) and
negative estrogen receptor values (p = 0.005), and thehigh expression of β-catenin was thus associated with
an adverse disease outcome.
We found no differences for the cytoplasmic ß-catenin
as well as for the membrane ß-catenin with respect to the
grading. Moreover, the cytoplasmic ß-catenin was as-
sociated significantly with a reduced OS in unifocal tumors
(p = 0.032). Our data suggest a wnt signaling pathway in
unifocal tumors. However, this pathway might not play an
important role in multicentric/multifocal tumors. Therefore
we assume differences in tumor biology between uni- and
multifocal tumors according to our results.
Niu et al. described an association between abnormal
β-catenin expression, positive lymph node status and
high histological grade (p < 0.01) as well as a significant
correlation between positive Her2 expression and abnormal
β-catenin expression [13]. Therefore, elevated β-catenin
expression appears to be linked with worse outcome for
the patients. However, differences concerning focality have
not been investigated.
Recent research has underlined the importance of
E-cadherin with respect to cell adhesion mechanisms.
Down-regulation of E-cadherin/catenin-mediated intercel-
lular adhesion is known to be an important step in the
acquisition of malignancy and metastasis. According to
Baranwal [14], down-regulation of E-cadherin is associated
with worse outcome and enhanced aggressiveness of the
tumor. Klopp et al. [35] also stated that decreased expres-
sion of E-cadherin is associated with breast cancer progres-
sion and resistance to therapy. Finally, loss of E-cadherin
expression is a hallmark of epithelial-mesenchymal transi-
tion (EMT), which is associated with a worse prognosis
[16]. In contrast, up regulation of E-cadherin/catenin com-
plex, which acts as a suppressor of tumor progression, has
been accomplished with a series of agents, some of which
can be used therapeutically [36].
Our finding of a significantly reduced expression of
E-cadherin in multicentric/multifocal tumours underline
and reinforce our view of a more aggressive behavior of
this tumor type. Since loss of E-cadherin is a marker of
EMT, it might be worthwhile to examine other EMT
markers such as MMPs, which lead to E-cadherin degrad-
ation [37], or vimentin in multicentric/multifocal versus
unifocal breast tumors.
MUC1 is a multifunctional epithelial glycoprotein known
to be overexpressed in most epithelial cancers. MUC1 can
promote proliferation and metastasis, whereas down
regulation of MUC1 expression inhibits cell migration
by inducing β-catenin relocation from the nucleus to the
cytoplasm and increases E-cadherin/catenin complex
formation [38]. In addition, MUC1 is coexpressed and
complexed with STAT1 (Khodarev et al. [39]), and it is
associated with decreased recurrence-free and overall
survival. This may explain why intracellular expression of
MUC1 is associated with worse prognosis [40], whereas
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correlated with a better outcome [41].
Using the anti-MUC1 antibody mPankoMab, which
recognizes a special, tumor-associated MUC1 epitope
[19], we previously observed a correlation between
MUC1 and the expression of the ER receptor [42]. In
the present study, we did not observe differences in
MUC1 expression between multicentric/multifocal and
unifocal breast cancer (p = 0.183). However, when looking
at the histopathological grading, multicentric/multifocal
carcinomas showed a statistically significant decrease in
staining with increased histology grade (p = 0.027) which
was in contrast to the MUC1 expression in unifocal breast
cancer of different grade.
According to the cytoplasmic PankoMab-staining no
differences were found with respect to the histology grade.
When looking at the overall survival (OS) the PankoMab
epitope on the membrane was however associated with a
better outcome, nevertheless only significant in G2 and
G3 unifocal tumors (p = 0.038).
Conclusions
In summary, differences regarding tumo rbiology are
obvious as fore the wnt signaling pathway might play
an important role in unifocal tumors and the PankoMab
epitope on the membrane associated with a better outcome
in G2 and G3 unifocal tumors.
Due to the small collective used for this study, we have
not confirmed and extended our earlier results which dem-
onstrated that multicentric/multifocal tumors as compared
to unifocal breast tumors correlate with a reduced survival
and relapse-free interval (Additional file 1: Figure S1).
Instead, we analyzed membrane associated breast cancer
markers as molecules to discriminate with respect to
focality between both entities. These results indicate that
the breast tumor biology differs depending on focality and
suggest a tendency for enhanced EMT in multicentric/
multifocal breast cancer. Further research is necessary on
the tumor biology of multicentric and multifocal tumors.
Additional file
Additional file 1: Figure S1. Kaplan-Meier survival curves were drawn
to compare Overall survival (OS) and relapse free survival (RFS) in unifocal
and multicentric/multifocal tumors.
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